Literature DB >> 28094081

Emerging Human Fetuin A Assays for Biomedical Diagnostics.

Sandeep Kumar Vashist1, E Marion Schneider2, A G Venkatesh3, John H T Luong4.   

Abstract

Human fetuin A (HFA) plays a prominent pathophysiological role in numerous diseases and pathophysiological conditions with considerable biomedical significance; one example is the formation of calciprotein particles in osteoporosis and impaired calcium metabolisms. With impressive advances in in vitro diagnostic assays during the last decade, ELISAs have become a workhorse in routine clinical diagnostics. Recent diagnostic formats involve high-sensitivity immunoassay procedures, surface plasmon resonance, rapid immunoassay chemistries, signal enhancement, and smartphone detection. The current trend is toward fully integrated lab-on-chip platforms with smartphone readouts, enabling health-care practitioners and even patients to monitor pathological changes in biomarker levels. This review provides a critical analysis of advances made in HFA assays along with the challenges and future prospects.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28094081     DOI: 10.1016/j.tibtech.2016.12.006

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  3 in total

1.  Comment to: Are fetuin-A levels beneficial for estimating timing of sepsis occurrence?

Authors:  Irene Karampela; Maria Dalamaga
Journal:  Saudi Med J       Date:  2019-01       Impact factor: 1.484

Review 2.  Advancements in electrochemical biosensing for respiratory virus detection: A review.

Authors:  Zhi Zhao; Changfu Huang; Ziyu Huang; Fengjuan Lin; Qinlin He; Dan Tao; Nicole Jaffrezic-Renault; Zhenzhong Guo
Journal:  Trends Analyt Chem       Date:  2021-03-12       Impact factor: 12.296

3.  Detection and Characterization of Phosphorylation, Glycosylation, and Fatty Acid Bound to Fetuin A in Human Blood.

Authors:  Markéta Kovářová; Hubert Kalbacher; Andreas Peter; Hans-Ulrich Häring; Triantafyllos Didangelos; Norbert Stefan; Andreas Birkenfeld; Erwin Schleicher; Konstantinos Kantartzis
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.